Comparing back (SARA) versus side (flank) positions for single-port robotic partial kidney tumor removal.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center, randomized 1:1 comparison of two patient positions for robot-assisted partial nephrectomy using the Da Vinci Single Port system. Participants with a single unilateral renal mass ≤7 cm will be randomly assigned to either the supine SARA anterior retroperitoneal approach or the standard flank approach. The primary outcome is a composite 'trifecta' of no intraoperative adverse events, negative surgical margins, and discharge on postoperative day 1, with multiple secondary outcomes including pain, time to ambulation, complications within 30 days, operative metrics, and 30-day kidney function. The trial is conducted at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy.

Why it matters

Who can join: the full rules

* Age ≥ 18 years;
* Presence of a single, unilateral, primary renal mass ≤ 7 cm in diameter (clinical stage cT1) documented CT scan
* No evidence of systemic disease or lymph node involvement;
* Candidate for robot-assisted partial nephrectomy using the Da Vinci SP platform;
* Signed informed consent
* Absence of solitary kidney status
* No previous partial nephrectomy/ies on the same kidney
* Absence of preoperative chronic kidney disease (CKD) stage 5
* Absence of any condition that makes mandatory or significantly more adequate the choice of a specific approach over the others (e.g., multiple previous major abdominal surgeries, horseshoe kidney, presence of stomas)

Where it's running

• ASST Grande Ospedale Metropolitano Niguarda
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Paolo Dell'Oglio, MD PhD — ASST Grande Ospedale Metropolitano Niguarda
• Study coordinator: Paolo Dell'Oglio, MD PhD
• Email: paolo.delloglio@ospedaleniguarda.it
• Phone: +393407981232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hyperspectral imaging to guide robot-assisted kidney tumor removal

  Doctors are testing a new imaging method during robotic kidney surgery to see if it helps identify tumor tissue and blood flow in adults with kidney tumors up to 7 cm.

  Recruiting University of Leipzig · Leipzig · NCT07803315

• MRI-based AI to classify and grade renal tumors

  This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07743749

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• Treating the main kidney tumor in metastatic kidney cancer during immunotherapy

  This trial will see if adding surgery or radiotherapy to the main kidney tumor helps people with metastatic clear‑cell kidney cancer who are already benefiting from anti‑PD1–based therapy live longer.

  Recruiting Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06903312

• Comparing systemic treatment alone to systemic treatment with added radiotherapy for kidney cancer with few metastases

  This study is testing if adding targeted radiation therapy to regular treatment can help people with kidney cancer that has spread a little to live longer without their cancer getting worse.

  Recruiting Phase 3 Samsung Medical Center · Seoul · NCT06467097

• Impact of kidney function on cancer drug levels in patients with metastatic kidney cancer

  This study is testing how kidney function affects the levels of cancer drugs in the blood for patients with metastatic kidney cancer to see if they need different doses for better results.

  Recruiting at 5 sites Institut du Cancer de Montpellier - Val d'Aurelle · Marseille and 4 other locations · NCT04823923

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.